3-amino-2-(2-chloro-6-fluorophenyl)-2,8-dihydro-6H-pyrano[3,4-c]pyridazine-4-carbonitrile hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃并[3，4-c]哒嗪
• 英文名称: 3-amino-2-(2-chloro-6-fluorophenyl)-2,8-dihydro-6H-pyrano[3,4-c]pyridazine-4-carbonitrile hydrochloride
• 英文别名: 3-Amino-2-(2-chloro-6-fluorophenyl)-6,8-dihydropyrano[3,4-c]pyridazine-4-carbonitrile;hydrochloride
• 化学式: C₁₄H₁₀ClFN₄O*ClH
• 分子量: 341.172
• InChiKey: UFANFIAKVUBTOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.73
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  吗啉 、 丙二腈 以 二甲基亚砜 、 乙酸乙酯 为溶剂， 以41%的产率得到哒嗪
  参考文献：
  名称：

  Novel compounds

  摘要：

  本发明涉及一种新型吡啶并嗪化合物，其化学式为I1，以及其药学和药理学上可接受的盐和水合物；以及它们的制备方法，用途和包含这些新型化合物的药物组合物。这些新型化合物在治疗中具有用途，特别是用于治疗2型糖尿病。

  公开号：

  US20020115663A1

文献信息

• Benzamidine derivatives
  申请人：——

  公开号：US20020123489A1

  公开（公告）日：2002-09-05

  Benzamidine derivatives are useful delta-opioid receptor modulators, agonists useful as analgesics and antagonists useful as immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

  苯甲酰胺衍生物是有用的δ阿片受体调节剂，作为镇痛剂有用的激动剂，作为免疫抑制剂有用的拮抗剂，抗炎药物，用于治疗神经系统和精神疾病的药物，用于药物和酒精滥用的药物，用于治疗胃炎和腹泻的药物，心血管药物和用于治疗呼吸系统疾病的药物。
• [EN] NOVEL PYRIDAZINE COMPOUNDS FOR THE TREATMENT OF DIABETES<br/>[FR] NOUVEAUX COMPOSES DE PYRIDAZINE POUR LE TRAITEMENT DE DIABETES
  申请人：BIOVITRUM AB

  公开号：WO2002026743A1

  公开（公告）日：2002-04-04

  The present invention is directed to novel pyridazine compounds of the formula (I) as well as pharmaceutically and pharmaceutically acceptable salts, and hydrates thereof; to a process for their preparation, their use and pharmaceutical compositions comprising said novel compounds. These novel compounds are useful in therapy, particularly for the treatment of type 2 diabetes mellitus.
• [EN] BENZAMIDINE DERIVATIVES<br/>[FR] DERIVES DE LA BENZAMIDINE
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2002048122A2

  公开（公告）日：2002-06-20

  Benzamidine derivatives of the formula I are useful delta-opioid receptor modulators, agonists useful as analgesics and antagonists useful as immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases. Wherein: X is a substituent selected from the group consisting of S and O; Z is a substituent selected from the group consisting of O(R5) and N(R6)(R7); the moiety -C(X)Z is substituted on the phenyl at the 3 or 4 position; n is an integer from 1 to 2; R1 is a substituent selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy(C1-6)alkyl, C1-6alkoxycarbonyl, C1-6alkyl(C1-6)alkoxycarbonyl, formyl, aryl, aryl(C1-6)alkyl, diaryl(C1-6)alkyl and heteroaryl(C1-6)alkyl; wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino, di(C1-4alkyl)amino, thrihaloC1-4alkyl and trihaloC1-4alkoxy; R2 and R3 are substituents independently selected from the group consisting of hydrogen and C1-6alkyl; Ar is aryl optionally substituted with one to three substituents selected from R4; R4 is a substituent selected from the group consisting of halogen, C1-6alkyl, C1-6alkoxy, aryl, aryl(C1-6)alkyl, heteroaryl, heteroaryl(C1-6)alkyl, amino, C1-6alkylamino, di(C1-6alkyl)amino, cyano, hydroxy, nitro, trihaloC1-4alkyl and trihaloC1-4alkoxy; alternatively, two R4 substituents may be fused together on adjacent carbon atoms to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH2)3-5- and -O(CH2)1-3O-; R5 is a substituent selected from C1-6alkyl; and R6 and R7 are substituents independently selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl and aryl(C1-6)alkyl, wherein cycloalkyl and aryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C1-4alkyl,C2-4alkenyl, C1-4alkoxy, C3-7cycloalkyl, trihaloC1-3alkyl and trihaloC1-3alkoxy; alternatively, R6 and R7 may be fused together to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH2)3-5- and O(CH2)1-3O-; and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.